Skip to content

LBRX LBRX Accrued Expenses

Accrued Expenses at other companies

MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$10.18M
Alto Neuroscience logo
Alto NeuroscienceANRO
$2M-1.8%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.41M-58.6%
Opko Health logo
Opko HealthOPK
$83.48M-26.3%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$293.28M+3.1%
Septerna, Inc. logo
Septerna, Inc.SEPN
$8.63M+98.3%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+163%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's accrued expenses?
LBRX (LBRX) reported accrued expenses of $3.06M in Q1 2026.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.